Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHOS-3: Angiotensin II in Catecholamine-Resistant Hypotension
NCT02338843Phase 3Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of Angiotensin II in Catecholamine-resistant hypotension, sponsored by La Jolla Pharmaceutical Company. Started Mar 2015; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Catecholamine-resistant hypotension
Beyond the preview
Go deeper on NCT02338843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338843.